Regulation of Nucleotide Metabolism with Nutrient‐Sensing Nanodrugs for Cancer Therapy

The continual growth of tumor cells requires considerable nutrient consumption. Methotrexate (MTX) is used to treat certain types of cancer by blocking the DNA and RNA productions through interfering one‐carbon metabolism and de novo purine and pyrimidine synthesis. However, treatment of MTX may cause many serious adverse effects, which hamper its clinical application. Herein, the authors synthesize ferrous ions, histidine, and MTX assembled nanoparticles (FHM) to deliver MTX at tumor site and enhance the sensitivity of tumor cells to MTX with histidine catabolism. Furthermore, fasting‐mimicking diet (FMD) is applied to intervene in the one‐carbon metabolism and enhance the cytotoxicity of MTX. Meanwhile, FMD treatment can significantly augment the cellular uptake and tumor accumulation of FHM nanoparticles. Due to the triple inhibitions of the one‐carbon metabolism, the proliferation of tumor cells is strongly disturbed, as which is highly replying on DNA and RNA production. Taken together, a 95% lower dose of MTX adopted in combined therapy significantly inhibits the growth of two types of murine tumors without evident systemic toxicity. This strategy may provide a promising nucleotide metabolism‐based nanomedicine for cancer therapy. Tumor cells show a higher activity of nucleotide anabolic pathway for uncontrolled proliferation. Triple inhibitions of one‐carbon metabolism and de novo pyrimidine or purine synthesis are achieved with ferrous ions, histidine, and methotrexate (MTX) assembled nanoparticles and fasting‐mimicking diet (FMD). With a 95% lower dose of MTX, the assembled nanoparticles efficiently inhibit the tumor growth together with FMD treatment.